Embolization Devices Market is expected to reach US$ 5.89 Billion by 2031

Embolization Coil Segment to Lead Embolization Devices Market Based on Product Type During 2025–2031

According to our new research study on “Embolization Devices Market Forecast to 2031 – Global Analysis – by Product Type, Application, and End User,” the embolization devices market size was valued at US$ 3.07 billion in 2024 and is projected to reach US$ 5.89 billion by 2031; it is expected to register a CAGR of 9.9% from 2025 to 2031. Major factors driving the embolization devices market growth include the rising prevalence of clinical conditions and burgeoning demand for minimally invasive techniques.

Embolization devices are medical tools used in a minimally invasive procedure wherein targeted blood vessels are intentionally blocked to control or stop blood flow. This technique is employed to treat conditions such as aneurysms, arteriovenous malformations (AVMs), tumors, and bleeding.

Embolization Devices Market, by Region, 2024(%)

Source: The Insight Partners Analysis

Embolization Devices Market Analysis Based on Segmental Evaluation:

Based on product type, the embolization devices market is categorized into embolization coils, plugs, beads, glues, and others. In 2024, the embolization coils segment held a significant embolization devices market share. Embolization coils are used in interventional procedures to block the blood flow in blood vessels. There are two types of embolization coils: detachable and pushable. Detachable embolization coils are used for the venous and arterial embolization in the peripheral vasculature. The coils are available in several rigidity, size, and shape specifications, and catheter compatibilities, among others, which render them suitable for various functions. The coils, generally made up of platinum, are placed with one-click mechanical detachment handle technology. Detachable coils are most useful for intracranial interventions or in conditions with an elevated risk of coil migration due to high vascular flow; they can be recaptured and repositioned several times before release, allowing more precise placement. Some detachable coils are released when a weld is split under pressure or electrolytically. For instance, in GDC Detachable Coils (Cook Medical) and Matrix Detachable Coils (Boston Scientific), the connection between the coil and the delivery wire dissolves when the operator applies a current to the delivery wire. Hydrogel coils are available as detachable coils. The Concerto Helix and 3D Detachable Coil Systems (Medtronic) offer helical and complex options for peripheral embolization, in diameters ranging from 2 mm to 20 mm.

Pushable coils are widely used for the mechanical occlusion of peripheral and visceral vessels. These coils are readily available, cost-effective, user-friendly, quickly deployed, and easy to use, which are perceived as their key advantages. Pushable coils are a standard, cost-effective, and time-saving tool for indications that require embolic agents. Hydrogel-coated pushable coils—e.g., AZUR Pushable 35 and 18 by Terumo Medical Corporation—benefit through increased filling capacity regardless of thrombus formation. Further, VortX Coils by Boston Scientific Corporation provide compact, complete vascular occlusion and efficient embolization. Embolic coils are used in the treatment of renal cancer, hepatocellular carcinoma, neuroendocrine tumors, aortic artery disorders, and peripheral vascular diseases.

The scope of the embolization devices market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In terms of revenue, North America dominated the embolization devices market share in 2024. The rising incidence of cardiovascular disease and an increased focus on preventive healthcare are among the key factors propelling the demand for embolization devices in the region. Additionally, government support for treatment, an aging population, and the growing awareness among both patients and physicians regarding interventional radiology options contribute to the rising utilization of embolization techniques in North America. The US holds a significant share of the embolization devices market in North America. In the US, the market is characterized by a high level of innovation, early adoption of emerging technologies, and a strong clinical focus on minimally invasive treatments. As per the study “Minimally Invasive Surgery in the United States, 2022: Understanding Its Value Using New Datasets,” the US exhibited a surging trend of minimally invasive surgeries (MIS), including robotic-assisted procedures, across both inpatient and ambulatory settings from 2016 to 2018. According to the National Cancer Institute, HCC is the most prevalent type of liver cancer in the US, accounting for over 80% of all cases. Healthcare providers recommend embolization procedures for treating conditions such as HCC, uterine fibroids, and brain aneurysms, given their lower risk profiles and quicker recovery times compared to traditional surgeries.

The embolization devices market in the US also benefits from substantial investments made in medical technology and robust clinical research supporting the efficacy and safety of embolization therapies. The study titled "Results from a United States Investigational Device Study of Adhesive Capsulitis Embolization in the Treatment of Shoulder Pain," conducted at Prostate Centers USA and published in February 2022, aimed to assess the safety and efficacy of arterial embolization for treating shoulder pain caused by adhesive capsulitis (AC). The findings demonstrated that adhesive capsulitis embolization (ACE) significantly reduced pain and improved shoulder function in patients who were irresponsive to conservative treatments. The study also highlighted statistically significant improvements in VAS (i.e., Visual Analog Scale) and SANE (i.e, Single Assessment Numeric Evaluation) scores a month after the procedure, which was followed by the persistence of these benefits through the six-month follow-up. Additionally, no major adverse events were reported, whereas minor adverse events subsided on their own without the need for intervention.

The presence of major players such as Medtronic, Boston Scientific, and Stryker ensures continuous innovation and competition in the US, keeping the market dynamic and progressive. Academic and medical institutions collaborate frequently with manufacturers to develop and evaluate new devices. In addition, The regulatory framework, although rigorous, supports a structured path of product approval and contributes to the embolization devices market growth.

Medtronic Plc, Cook Medical Holdings LLC, Stryker Corp, Boston Scientific Corp, Terumo Corp, Johnson & Johnson, Abbott Laboratories, NeuroSafe Medical Co. Ltd, Wallaby Medical, Sirtex Medical Ltd, GEM srl, Balt, Lepu Medical Technology Beijing Co Ltd, INVAMED, Meril Life Sciences Pvt Ltd, Merit Medical Systems Inc, and Lifetech Scientific Corp are among the leading companies profiled in the embolization devices market report.

Based on product type, the embolization devices market is segmented into embolization coils, plugs, beads, glues, and others. By application, the embolization devices market is segmented into neurology, peripheral vascular disease, oncology, urology, and others. Based on end user, the embolization devices market is segmented into hospitals, ambulatory centers, and others. Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com